StockData
Scribe Therapeutics, Inc. logo

Scribe Therapeutics, Inc. (SCTX) stock

SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$15.77+0.40 (+2.60%)

Close on Nov 17, 2026Market cap $39.19MP/E –Yield –

Earnings

Scribe Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2026
$1.60M
EPS, Q3 FY2026
$0.68
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Scribe Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026after the close$1.60M–$0.68Release
Q2 FY2026ended Jun 30, 2026Sep 2, 2026during market hours$1.90M–-$2.62Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Scribe Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Scribe Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Scribe Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?